Table 4.
Total numbers and percentages of isolates susceptible to selected antibioticsa
| Organism | Total no. of KPC producers | No. of isolates susceptible/total (%) |
||||||
|---|---|---|---|---|---|---|---|---|
| Ceftriaxone | Cefepime | Imipenem | Piperacillin-tazobactam | Amikacin | Ciprofloxacin | ESBL | ||
| K. pneumoniae | 333 | 21/288 (7) | 31/300 (10) | 89/316 (28) | 7/299 (2) | 114/330 (35) | 46/332 (14) | 80/332 (24) |
| E. coli | 61 | 10/52 (19) | 10/51 (20) | 44/53 (83) | 24/52 (46) | 39/60 (65) | 10/60 (17) | 37/60 (62) |
| P. aeruginosa | 99 | 2/92 (2) | 6/98 (6) | 6/95 (6) | 16/98 (16) | 62/95 (59) | 7/98 (7) | NDb |
| A. baumannii | 41 | 0/40 (0) | 0/40 (0) | 11/33 (33) | 2/34 (6) | 4/41 (10) | 0/41 (0) | ND |
a
Data, including those on ESBL detection, are from the participating hospitals' antimicrobial susceptibility reports. The susceptibility breakpoints (μg/ml) for all isolates are as follows: ≤8, cefepime; ≤4, imipenem; ≤16, amikacin; ≤1, ciprofloxacin. The susceptibility breakpoints of ceftriaxone are ≤1 μg/ml for Enterobacteriaceae and ≤8 μg/ml for P. aeruginosa and A. baumannii. The susceptibility breakpoints (μg/ml) of ceftriaxone are ≤1 and ≤8 for the Enterobacteriaceae P. aeruginosa and A. baumannii. The susceptibility breakpoints (μg/ml) of piperacillin-tazobactam are ≤64 and 4 for P. aeruginosa and ≤16 and 4 for A. baumannii.
b
ND, not done.